Back to top
more

Tonix Pharmaceuticals (TNXP)

(Delayed Data from NSDQ)

$0.17 USD

0.17
1,857,130

+0.01 (5.31%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.17 0.00 (0.89%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Tonix Pharmaceuticals Holding Corp. [TNXP]

Reports for Purchase

Showing records 141 - 154 ( 154 total )

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 141

11/25/2013

Company Report

Pages: 8

3Q13 Recap - TNX-102 SL Data Remains On Track for 2H14

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 142

11/13/2013

Company Report

Pages: 17

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 143

10/01/2013

Company Report

Pages: 29

We initiate with a Buy rating and $8.50/share price target.

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 75.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 144

10/01/2013

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 145

09/04/2013

Company Report

Pages: 6

The Company recently filed their second quarter 2013 10-Q

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 25.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 146

08/16/2013

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 147

07/15/2013

Company Report

Pages: 14

Initiate coverage with a price target of $9.28

Provider: SEETHRUEQUITY, LLC

Analyst: TANDON A

Price: 50.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 148

06/07/2013

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 149

04/12/2013

Company Report

Pages: 6

Full steam ahead for TNX-102 SL in FM

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 25.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 150

03/12/2013

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 151

12/05/2012

Company Report

Pages: 22

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 152

11/05/2012

Company Report

Pages: 23

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Medical - Drugs

Record: 153

09/21/2012

Company Report

Pages: 6

Tonix is set to begin its first pivotal clinical trial early next year,

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 25.00

Research Provided by a Third Party

Company: Tonix Pharmaceuticals Holding Corp.

Industry: Unclassified

Record: 154

04/26/2012

Company Report

Pages: 21

Spring Tonix for Growth Investors

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 75.00

Research Provided by a Third Party